A Phase 1 Investigator Sponsored Study of Selinexor in Combination With Daunorubicin and Cytarabine in Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Trial Profile

A Phase 1 Investigator Sponsored Study of Selinexor in Combination With Daunorubicin and Cytarabine in Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Suspended
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Selinexor (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 31 Oct 2017 Some discrepancy was found in the study status. For confirmation I have sent mail to the investigator and waiting for the reply (levla.khavarian@moffitt.org).
    • 23 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top